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1  Introduction
The objective of this paper is to provide an overview of economic evaluation of 
personalized medicine (PM), focusing particularly on the use of cost-effective-
ness analysis (CEA) and other methods of valuation.
We begin with definitions to clarify the landscape and scope of this paper. 
The term “personalized medicine” generally is used to refer to targeting of 
health care based on genetic information, although it also can be thought of 
more broadly as targeting based on any characteristic such as patient prefe-
rences. Recently, a National Academy of Sciences report used the term “preci-
sion medicine” – the use of genomic, epigenomic, exposure, and other data 
to define individual patterns of disease, potentially leading to better indivi-
dual treatment. It was felt by the committee that this definition conveys a more 
accurate image of diagnosis that is person-centered and multifaceted (National 
Research Council 2011). PubMed has a category for “individualized medicine,” 
defined as “therapeutic approaches tailoring therapy for genetically defined 
subgroups of patients.” In earlier years, the more commonly used term was 
“pharmacogenomics,” which is a narrower concept, defined as the analysis of 
the effect of genomics – in particular, genetic variation (polymorphisms) – on 
drug response.
Economic evaluation can encompass a wide range of topics and methods, 
including some that would be more narrowly considered as economic analyses 
based on standard welfare economic theory as well as others derived from fields 
such as decision analysis, operations research, and behavioral econo mics. The 
most commonly used form of economic evaluation is CEA (Gold et  al. 1996). 
Related approaches include cost-benefit analysis, decision analysis, stated choice 
methods/conjoint analysis/discrete choice experiments and willingness-to-pay, 
budget impact analysis, burden of illness studies, value of information analysis, 
and multi-criteria decision analysis.
Regardless of how one defines PM, it is clear that the trend towards greater 
targeting of interventions to sub-populations is inevitable given our growing 
understanding of disease. For example, there have been over 400 new genetic 
tests since 2010 (Khoury et al. 2012a), and an Agency for Healthcare Research and 
Quality (AHRQ) horizon scan of genetic tests for cancer found that over 100 tests 
are clinically available – a 67% increase in 4 years (Raman et al. 2011). It is hoped 
that PM will result in higher-quality, lower-cost health care because of opportuni-
ties to offer patients therapies that are more effective for them and avoid treat-
ments that will not be safe or effective.
Several reviews have provided overviews of economic opportunities and chal-
lenges for economics of PM using a variety of perspectives. Deverka et al. (2010) 
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noted that there is great potential for genetic testing to be cost-effective and even 
cost-saving, although they also noted that its ability to do so will depend on many 
factors. A study by McKinsey Consulting examined the major barriers to adoption 
of PM from a business perspective (Davis et al. 2009). They concluded that there 
is poor alignment of incentives across key business stakeholders (e.g., payers, 
providers, pharmaceutical and biotech companies, diagnostic companies). For 
example, they noted that a test that reduces cancer treatments may reduce physi-
cian revenues, a test that increases the number of patients using treatments with 
marginal health benefits may increase health plan costs, and some applications 
do not offer potential for economic gains from development of companion tests.
In a commentary, Katrina Armstrong noted that genomics could potentially 
“bend the cost curve” but that several steps would need to be taken to enable 
it to do so, including effective clinical decision support, information systems, 
guidelines about how to manage genomic information unrelated to the clinical 
question of interest, and testing costs that are lower than the cost of the interven-
tions (Armstrong 2012). However, despite the conceptual appeal of this assertion, 
it is also possible that PM will simply increase costs without increasing benefits. 
Difficult decisions will have to be made about how to assess the value of these 
technologies, which technologies will be adopted, and who will pay for them – all 
areas that economics can address.
PM is also of interest because of the increased emphasis on patient-centered 
care that takes into account patient variability, including genetic differences. 
The authorizing legislation for the Patient-Centered Outcomes Research Institute 
(PCORI) states that research shall be designed to take into account potential for 
differences in the effectiveness of health care as used with various subpopula-
tions. Genetic factors may cause treatment effects to vary across individuals, 
along with clinical factors, personal and behavioral factors, and the health care 
delivery context.
Despite the conceptual appeal of personalized medicine, there are many bar-
riers to its adoption. Key challenges include (1) negotiating shifting industry par-
adigms; (2) balancing innovation and regulation; (3) building the evidence base; 
and (4) determining value and reimbursement. Figure 1 provides a conceptual 
framework by placing economic analyses within a larger context. This framework 
notes that the use of genomic information is part of a translational continuum –  
from basic research, to clinical research, to policy research – that determines 
adoption and health and economic outcomes. Key determinants of adoption and 
outcomes include utilization, tradeoffs as defined by preferences and by eco-
nomic benefits/costs, and evidence. Economics permeates each of these areas, 
with a central focus on preferences and demand based on the utility obtained 
from consuming goods and services.
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2   Does Personalized Medicine Require Different 
Evaluation Approaches?
It is clear that, historically, the evaluation of diagnostics has been different from 
that of drugs (Phillips et al. 2006) – and most PM interventions include diagnos-
tics. The regulatory pathways, the measures of clinical utility, and the number 
and scope of economic analyses have been different for diagnostics. However, 
one reason is that diagnostics have typically been low-cost, low-risk interven-
tions and thus the level of scrutiny has been less. With the advent of diagnostics 
based on genetic information, that situation has changed such that PM diagnos-
tics are often high-cost, higher-risk interventions that guide clinical care, and 
thus evaluation approaches may be shifting.
In general, the literature suggests that standard methods can be applied to 
PM; however, there are a number of complexities of PM that may require different 
approaches to economic evaluation (Phillips et  al. 2006). The field of genetics 
has historically not been a focus of economists or health services researchers, 
and understanding these technologies can require more interdisciplinary work 
across basic, clinical, and social scientists. Laboratories and coding systems play 
a large role in PM adoption, adding another layer of complexity. The Food and 
Drug Administration (FDA) does not directly regulate most diagnostics and thus 
does not assess their clinical utility, often resulting in less information available 
Basic
research
Clinical
research Policy research
Utilization
Trade-offs
Knowledge translation: To ensure best use of findings
Diverse populations
Who is affected?
Evidence
Who uses tests
and barriers to
adoption
Preferences and
benefits vs.
costs for
patients,
providers and
society
Data to guide
policy decision-
making
Adoption Outcomes
Policy research on personalized medicine requires...
Figure 1 Conceptual Framework for Personalized Medicine Translation.
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on their efficacy and effectiveness. Emerging PM tests are often complex techno-
logies – based on algorithms and panels of genes – and they may be used for mul-
tiple purposes, so they can be harder to assess than single gene tests. Genomic 
technologies based on inherited mutations such as BRCA testing may impact 
family members, requiring more complex models that incorporate both the initial 
patients and their families.
Two key characteristics of PM that require more complex analyses and are 
often poorly understood are (1) diagnostics can be characterized by varying 
degrees of analytic validity, clinical validity, and clinical utility, and (2) dia g-
nostics provide information rather than directly changing outcomes. A useful 
framework for understanding the evaluation of genetic tests and the role of ana-
lytic validity, clinical validity, and clinical utility is the framework developed by 
the Centers for Disease Control and Prevention (http://www.cdc.gov/genomics/
gtesting/ACCE/index.htm). The ACCE framework uses key criteria for evaluating 
a genetic test – analytic validity, clinical validity, clinical utility and associated 
ethical, legal and social implications:
 – Analytic validity – How accurately and reliably the test measures the geno-
type of interest.
 – Clinical validity – How consistently and accurately the test detects or predicts 
the intermediate or final outcomes of interest.
 – Clinical utility – How likely the test is to significantly improve patient 
outcomes.
Economic evaluations often confuse analytic and clinical validity; for example, 
they will model a test as 100% accurate because its analytic validity is 100% – but 
its clinical validity is typically less than that. Thus, determining the accuracy of 
tests can be complicated. In addition to the conceptual challenges, accuracy can 
be difficult to assess because it will also vary depending on the laboratory where 
it is conducted.
Another key characteristic of PM that increases the complexity of analyses is 
that diagnostic tests produce information rather than direct value. Thus, economic 
evaluations need to consider how that information impacts treatment decisions 
and outcomes, and both the test and intervention need to be considered simul-
taneously. There may be a variety of testing options, different pathways linking 
tests to therapies, and tests that apply to several drugs. Figure 2 shows that the 
actual effectiveness and cost-effectiveness of diagnostics depend upon whether 
a test is ordered, whether the test accurately identifies who should get treatment, 
and whether patients and providers act in accordance with test results. However, 
economic analyses often make simplifying assumptions about these factors that 
do not reflect real-world test characteristics and behaviors.
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3   What is Known about the Economic Evaluation 
of Personalized Medicine?
Early studies focused on reviews of the societal and economic implications of per-
sonalized medicine, while more recently a number of empirical analyses and cost-
effectiveness analyses have been published. Examples include an early review of 
societal and economic implications (Phillips et al. 2000); a primer on applying 
CEA and cost-benefit analysis to pharmacogenomics (Phillips et al. 2003); and a 
proposal for a resource allocation framework from a population perspective using 
CEA and cost-of-illness studies (Phillips and Van Bebber 2005). Many others have 
since published conceptual reviews of the field. For example, Khoury and col-
leagues laid out a population approach to precision medicine that includes eco-
nomic analyses and expertise (Khoury et al. 2012b).
One of the earliest empirical studies concerned the potential role of phar-
macogenomics in reducing adverse drug reactions (Phillips et al. 2001). It sug-
gested that drug therapy based on individuals’ genetic makeups may result in 
a clinically important reduction in adverse outcomes. This study required the 
integration of two research areas: basic and clinical research on genetics and 
population science on adverse drug reactions and quality of care – and a team 
comprised of basic and clinical scientists and social scientists.
One of the earliest reviews of pharmacogenomics identified only 11 eco-
nomic evaluation studies, predominantly examining inherited mutations 
(Phillips and Van Bebber 2004). Since then, there have been several structured 
reviews to synthesize and characterize the body of evidence on the economic 
value of clinical genomic applications (Giacomini et  al. 2003; Carlson et  al. 
2005; Vegter et al. 2008; Beaulieu et al. 2010; Wong et al. 2010; Djalalov et al. 
2011). These reviews have aggregated and drawn conclusions about the cost-
effectiveness of various types of PM applications, assessed the quality of the 
available evidence, and proposed methodological standards that should be put 
in place to ensure that economic evaluations are producing the information 
Test ordered Test identifies whoshould get treatment
Actual effectiveness and cost-effectiveness of testing strategies
Treatment matches
   test results
Figure 2 The Sequence of Events for Diagnostic Testing.
Source: Phillips et al. 2009.
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needed for decision-making. Our assessment of the conclusions from these 
reviews is:
 – Economic evaluations have only been conducted on a fraction of the avail-
able genomic tests and on limited topics such as hepatitis C and breast 
cancer. However the evidence base is growing and at an accelerating rate.
 – Studies vary in terms of how they define the topic of focus and how they use 
different search terms, thus making it difficult to assess the evidence base as 
a whole.
 – A majority of the economic evaluations identified in these reviews are CEAs 
followed by cost-utility analyses, with fewer cost-benefit analyses and cost 
minimization analyses.
 – A majority of studies included in these reviews found PM interventions to 
have favorable CEA ratios, although fewer interventions were cost-saving. 
Beaulieu et al. (2010) noted that parameters that significantly impacted cost-
effectiveness and that should be included are biomarker prevalence, popula-
tion ethnicity, pharmacogenomic treatment effect, and cost of genomic data 
collection and analysis.
 – Assessments of the quality of the CEAs suggest general adherence to quality 
guidelines with some exceptions, and that quality is improving over time. 
Wong et al. (2010) concluded that the quality of studies could be improved 
by careful evaluation of the clinical validity and potential clinical utility of 
proposed biomarkers.
There are two major challenges to assessing the economic valuations of PM. 
First, there are no straightforward means by which to search for these studies in 
PubMed. There is no Major Exact Subject Heading (MeSH) in PubMed for “person-
alized medicine.” Relevant studies have been coded with a variety of terms such 
as “pharmacogenetics” and “genetic testing.” In 2010, a MeSH term for “indi-
vidualized medicine” was added to PubMed, including a subheading for “econo-
mics.” But only a fraction of the published studies have been coded so far using 
this term. Second, there is currently no consolidated source of information on the 
economic value of PM that includes a range of evaluation methods. The evidence 
base in the published literature on PM remains scattered thus making it difficult 
to draw conclusions about the value of PM in general and identify its most appro-
priate uses and applications. There have been recent efforts to aggregate PM evi-
dence, such as the National Institutes of Health (NIH) Genetic Test Re gistry, the 
Genomic Applications in Practice and Prevention Network (GAPPNet), and the 
Pharmacogenomics Knowledgebase (PharmGKB). A limitation of these consoli-
dated resources, however, is that they focus on the clinical and analytic charac-
teristics of the genetic test rather than economic information.
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Since 2008, the University of California, San Francisco Center for Transla-
tional and Policy Research on Personalized Medicine (TRANSPERS) has con-
ducted interconnected projects on utilization, preferences, cost-effectiveness, 
regulation, reimbursement, evidence development, diverse populations, and 
health policies. Findings emerging from these studies are summarized in this 
section.
3.1   Lack of Evidence on Personalized Medicine  
in Real-World Settings
Two TRANSPERS studies described gaps in the PM evidence base and how these 
could be addressed (Phillips 2008; Phillips et al. 2009). Human Epidermal Growth 
Factor Receptor 2 (HER2) testing to target trastuzumab treatment for patients with 
breast cancer is perhaps the best known example of testing to target treatment. HER2 
testing determines which patients overexpress the gene HER2; for those 20–30% 
of patients, trastuzumab is highly effective. Trastuzumab and an accompany-
ing test were approved in 1998 for patients with metastatic breast cancer and its 
use was expanded to patients with early-stage breast cancer after 2005. HER2 
testing is now recommended for all patients with invasive breast cancer, and only 
patients with positive test results are recommended for trastuzumab treatment. 
There is no consensus about optimal testing methods. Guidelines recommend 
using either immunohistochemistry (IHC), with indeterminate results confirmed 
by fluorescence in situ hybridization (FISH), or FISH alone, to determine HER2 
status. Although FISH is a better predictor of response to treatment, immunohis-
tochemistry costs substantially less and is more easily performed in community 
laboratories.
There was little available information on the actual use of HER2 testing in 
clinical practice, including whether all eligible patients receive testing, the 
impact on follow-up testing and changes in treatment decisions, and access to 
testing by underserved populations. At the time of our analyses, there was little 
or no information on whether women who were uninsured, on Medicaid, or 
minorities received testing and the extent to which women received IHC or FISH 
or both. There was evidence to suggest that a large percentage of tests were inac-
curate and that women who tested negative were still getting treatment – and 
conversely, women who tested positive did not always get treatment – especially 
lower income women. We found that most of the CEAs conducted had assumed 
perfect testing and use of test results – and thus may have overstated the actual 
cost-effectiveness of testing and treatment in clinical practice.
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Several recommendations to improve the evidence base emerged from this 
study and others. A first step is to document and disseminate gaps in knowledge 
about actual clinical practices. In the case of HER2 testing, clinicians and insurers 
often were surprised to hear about the evidence gaps.
Second, there is a need to standardize billing codes, laboratory procedures and 
documentation, claims information, and medical records for PM testing to enable 
better analyses of access and utilization. It is often impossible to identify the use of 
testing in administrative databases because of coding issues. For example, without 
chart review, the use of IHC and FISH for HER2 detection cannot be distinguished 
reliably from the same types of tests performed for other indications. Administra-
tive claims and medical records may not match; we found a mismatch for HER2 
testing claims and records about 25% of the time (Liang et al. 2011).
A third need is to examine the impact of policies intended to reduce data 
gaps and encourage more appropriate use of interventions. One example is the 
policy change implemented by United Healthcare in 2006, after it was found that 
many patients prescribed trastuzumab had missing or negative test results (L. 
Newcomer, personal communication, August 14, 2008). Its policy required clini-
cians to submit documentation of a positive HER2 test result with the first tras-
tuzumab claim. The rate of submitted claims for trastuzumab decreased after the 
policy implementation, suggesting that it may reduce inappropriate use. Because 
of this policy and other efforts to improve laboratory procedures, the plan has 
more information about why errors are made in HER2 testing and has been able 
to implement quality improvement programs. Although there are potential disad-
vantages to such policies, they may warrant consideration for some technologies.
Lastly, we need to develop creative approaches to obtaining evidence. Cur-
rently, few databases link testing, test results, treatment, and outcomes, and no 
system in the United States regularly monitors tests after their adoption. Work 
being done by PCORI to enhance the use of observational databases, including 
more sophistical statistical approaches and greater linkages, should improve our 
ability to assess real-world practice. Linking groups such as payers with research-
ers is also a fruitful approach; TRANSPERS has worked with several health plans 
and their foundations and, most recently, the Health Care Cost Institute has 
aggregated claims data from several of the nation’s largest insurers.
3.2   Will Personalized Medicine be Cost-saving or More  
Cost-Effective than Alternatives?
Our work to date on Lynch syndrome and gene expression profiling for breast 
cancer suggests that PM interventions may be cost-effective – given certain 
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assumptions – but that one cannot assume that PM will be cost-saving or reduce 
costs of care.
Lynch syndrome is the most common genetic cause of colorectal cancer. 
Testing for the syndrome can identify family members who will benefit from 
increased interventions for cancer prevention and early treatment. We conducted 
a CEA of testing for Lynch syndrome, comparing various testing strategies (Lada-
baum et al. 2011). Among tumor-testing strategies, IHC followed by BRAF gene 
mutation testing was preferred, with an incremental cost-effectiveness ratio of 
$36,200 per life-year gained. We concluded that testing for Lynch syndrome 
could yield substantial benefits at acceptable costs, particularly for women who 
begin regular screening and have risk-reducing surgery.
Gene expression profiling (GEP) testing for breast cancer provides informa-
tion about cancer recurrence and chemotherapy decisions. Several companies 
offer GEP testing for breast cancer, but the OncotypeDX™ breast cancer assay is 
the most commonly used test, and is covered by insurance in the United States 
despite a cost of almost $4000 per test. We conducted a CEA of GEP for breast 
cancer, comparing the most commonly used test (OncotypeDX™) with a common 
clinical algorithm developed by the National Comprehensive Cancer Network 
(NCCN). Preliminary results suggest that using GEP may be more cost-effective 
than relying on clinical algorithms but that there is a great deal of uncertainty 
around these results, and results are heavily impacted by assumed use of chemo-
therapy following testing (Marshall et al. 2012).
In addition, we conducted an analysis to examine the association between GEP 
testing and use of chemotherapy, serious chemotherapy-related adverse effects, 
and total charges during the 12 months following diagnosis (Haas et al. 2011). Data 
were from administrative claims and medical records from a national health plan. 
Our findings suggest that GEP testing was most commonly used in women at mod-
erate (versus low or high) clinical risk of recurrence (52% vs. 25% of low-risk women 
and 5.5% of high-risk). While GEP testing was associated with an overall decrease 
in adjuvant chemotherapy, we did not find differences in serious chemotherapy-
associated adverse events or charges during the 12 months following diagnosis.
3.3  The Method of Targeting
Assessing the impact of a targeted intervention on costs and health outcomes 
requires explicit consideration of the method of targeting – but we found in a 
review of breast cancer studies that few studies explicitly evaluated the relation-
ships among the method of targeting, the accuracy of the targeting test, and out-
comes of the targeted intervention (Elkin et al. 2011). Studies that did evaluate the 
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method of targeting found that characteristics of targeting tests had a substantial 
impact on outcomes.
Nearly all diagnostic tests give an inherently continuous result that is cat-
egorized as a basis for action, and nearly all tests must be considered imper-
fect predictors of a true state, rather than certain indicators of the truth. When 
the outcome of a targeted intervention depends on the presence or absence of 
the target, test results are generally dichotomized, based on some threshold 
applied to the underlying continuous result. In these cases, economic evalua-
tion of a targeted strategy requires explicit consideration of test performance 
relative to a gold standard and how the performance characteristics of the 
test in the population of interest – sensitivity, specificity, positive predictive 
value, and negative predictive value – influence the use and outcomes of the 
intervention.
A CEA restricted to a cohort with positive test results captures only part 
of the full range of health and economic impacts of implementing a targeted 
intervention because it ignores negative test results and their consequences 
(Figure 3). When the targeting test is very expensive, a CEA that ignores indi-
viduals with negative test results would exclude these costs. Such an analy-
sis would also exclude the negative health consequences of failing to give the 
intervention to those with a false-negative result – individuals who truly have 
the target.
Second, economic evaluation of risk-targeted interventions requires explicit 
consideration of the threshold risk criterion. Figure 4 shows hypothetical dis-
tributions of the predicted risk of disease recurrence in two groups of women 
treated for early-stage breast cancer: those who will, in fact, experience a recur-
rence and those who will not. In Panel A, the threshold is relatively strict; the 
Test result and action Target status Consequence
+
+
Intervention
-
No intervention
Test
+
-
-
True positive
False positive
False negative
True negative
Figure 3 Possible Test Results in an Economic Evaluation of a Targeted Intervention.
Source: Elkin et al. 2011.
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intervention is given to a small proportion of patients, all of whom would have 
had a disease recurrence in the absence of the intervention. When the crite-
rion is more lenient and individuals with a lower predicted risk are eligible for 
the intervention (Panel B), more patients who would have recurred receive the 
intervention but so too will some women who never would have had a disease 
recurrence. The tradeoffs associated with the threshold risk criterion – and the 
resulting costs, risks, and benefits of the test and intervention – will influence 
the cost-effectiveness of a risk-targeted strategy.
3.4  Behavior of Family Members
Behavior of family members can be a key factor in determining the value of PM for 
inherited mutations. In the CEA of Lynch syndrome screening, we found that it is 
especially important to identify and counsel relatives of the persons being tested 
because the benefits of screening cannot be realized otherwise (Kreft 1995). We 
found that the number of relatives tested per proband (person presenting with 
Lynch) was a critical determinant of both effectiveness and cost-effectiveness, 
with testing of 3 to 4 relatives required for most strategies to meet a threshold of 
$50,000 per life-year gained. However, there is a lack of empirical evidence on 
whether family members will change their behaviors.
No intervention
No intervention
Predicted recurrence risk
Intervention
Intervention
Will recur
Will not recur
Predicted recurrence risk Will recur
Will not recur
Figure 4 Thresholds for a Targeted Intervention by Predicted Risk and Actual Outcome.
Source: Elkin et al. 2011.
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3.5  Patient and Provider Preferences
Patient and provider preferences may affect the cost-effectiveness of person -
alized medicine. Our conjoint analysis found that individuals have a relatively 
high value for Lynch syndrome screening – if such screening is private and 
accurate (Knight 2011). Each choice task included two hypothetical genetic test 
alternatives (with varying attributes for accuracy, privacy, and cost), a no-test 
option, and a hypothetical level of colorectal cancer risk. We found that privacy 
was the most valued attribute. Most participants would have genetic testing to 
reduce the risk of dying from colorectal cancer in the best scenario (no false-
negatives, results disclosed to primary care physician), while only 41% would 
have genetic testing in the worst case (20% false-negatives, results disclosed to 
insurance company). The overall monetary value of testing relative to no testing 
was $622.
Our utilities study and cost-utility study also suggested that patient prefer-
ences may play a large role in uptake of testing, and thus impact the cost-effec-
tiveness of genetic testing. In our time tradeoff study, we found that preferences 
for the potential outcomes of testing vary substantially, calling into question the 
extent to which patients would avail themselves of such testing if it were offered 
(Kuppermann et al. 2012). Less than half of the sample assigned higher scores to 
undergoing Lynch testing and receiving negative results versus foregoing testing. 
This suggests that knowing that one does not carry a Lynch syndrome-causing 
mutation may not be viewed as a net gain to many of the people to whom current 
guidelines are directed.
In our cost-utility analysis of Lynch syndrome screening, we found that cost-
effectiveness of genetic testing decreased when quality-of-life considerations 
were included, although testing was still relatively cost-effective (Wang et  al. 
2012). The duration and magnitude of decreases in quality-of-life after decisions 
related to testing and surgeries were key determinants of the cost-effectiveness 
of screening. Similarly, in an ongoing study of the cost-effectiveness of gene 
expression profiling for breast cancer, we found that patient and physician 
preferences on treatment choices – and thus the proportion of women receiving 
chemothe rapy – have a large impact on cost-effectiveness of testing (Marshall 
et al. 2012).
Provider preferences are also likely to be important to cost-effectiveness. 
We found in a study of colorectal cancer screening that physicians were more 
likely to underestimate how much patients valued screening, which could 
affect screening rates because physicians may be less likely to recommend 
screening if they believe that their patients do not value it (Marshall et  al. 
2009).
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3.6  Assessing the Value of Personalized Medicine
Payers struggle with how to assess the value of PM for making coverage and reim-
bursement decisions. We have conducted several studies exploring how payers 
make coverage and reimbursement decisions on PM technologies (Trosman et al. 
2010, 2011). Many of these studies have emerged from interviews with our Evi-
dence and Reimbursement Policy Council, which include senior executives from 
the seven largest United States health insurance plans, leading regional plans, 
and pharmacy benefits management companies as well as thought leaders with 
industry, government, and Medicare perspectives.
Of particular relevance is a study of the health technology assessment 
guidelines used by payers in decision making (Trosman et  al. 2011). We found 
that payers typically used one or more of seven health technology assessment 
guidelines:
 – Blue Cross Blue Shield Technology Evaluation Center (BCBS TEC)
 – Emergency Care Research Institute (ECRI)
 – Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
 – Institute for Clinical and Economic Review (ICER)
 – United States Preventive Services Task Force (USPSTF)
 – UpToDate
 – Hayes
Payers varied greatly in how many guidelines they used, with some payers 
using all or most of them while others used one or two. Guidelines varied as 
to their inclusion of costs and economic analyses, from minimal to a central 
focus. Payers noted that they expect to use cost-effectiveness criteria in the 
future and thus the groundwork should be laid now. Payers generally stated 
that they do not expli citly use economic analyses in their decision making – 
although they expect to do so in the future. As one payer stated, “We don’t 
use cost-effectiveness in decisions today, but in the future state, it’s critical 
that we do that and get some agreement on how we measure the value and 
cost-effectiveness. The groundwork needs to be lain but it’s not there today” 
(Trosman et al. 2011: p. 21s).
Payers noted that they focused first on clinical utility in making decisions –  
but when this was uncertain, they wanted information on other nonclinical 
factors such as cost-effectiveness. However, payers felt that the guidelines were 
lacking in information on cost-effectiveness – 82% of payers stated that this was 
a shortcoming in health technology assessment reviews.
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3.7  Diffusion of Personalized Medicine
Diffusion of PM appears to lag for certain subgroups, with implications for uti-
lization and cost-effectiveness. For diverse populations, our findings document 
racial/ethnic and social gaps in access to and use of PM diagnostics. One reason 
may be because a perception of one’s family history risk may vary by race/ethnic-
ity (Ponce et al. 2012). On the supply side, PM diagnostics, such as GEP to inform 
use of adjuvant chemotherapy for early-stage breast cancer, have not been ade-
quately validated in minority populations (Odierna et al. 2011). Public payers tend 
to be less generous in BRCA gene mutation testing than private payers, despite 
professional guidelines establishing BRCA testing as standard of care (Wang et al. 
2011). Yet even among women with the same private insurance coverage, use of 
GEP was lowest for low-income women (Haas et  al. 2011). Taken together, our 
studies suggest that socioeconomically vulnerable subgroups may lag behind in 
harnessing the bene fits of PM, and the barriers stem from both preferences and 
supply-side policies.
4   Opportunities, Challenges, and Research 
Questions
4.1  Develop and Apply Multiple Methods of Assessing Value
The most commonly-used approach to measuring the economic value of health 
care interventions, including PM, is CEA. Furthermore, a particular type of CEA – 
cost-utility analysis (CUA) using quality-adjusted life years, is the recommended 
approach for what has been termed the “reference case” for comparability 
across studies (Gold et al. 1996). Despite the usefulness of CEA and CUA, there 
are a number of political and methodological barriers to using these methods, 
and thus the field can move forward by using a broader conception of “value” 
and wider use of alternative methods for assessing value.
Many commentators have noted that decision-makers are often reluctant to 
use CEA because of concerns about the appearance of rationing care based on 
costs and concerns about how such analyses are conducted (Neumann 2005). 
These concerns are highlighted by the restriction on use of cost-effectiveness 
analyses in the legislation establishing PCORI. PCORI is prohibited from using 
“dollars-per-quality adjusted life year (or similar measure that discounts the 
value of a life because of an individual’s disability) as a threshold to establish 
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what type of health care is cost effective or recommended.” As noted by PCORI 
Executive Director Joe Selby, “You can take it to the bank that PCORI will never 
do a cost-effectiveness analysis” (See http://insidehealthpolicy.com/Inside-
Health-General/Public-Content/pcori-head-vows-not-to-do-cost-effectiveness-
studies-but-notes-gray-areas/menu-id-869.html). However, he did note that 
costs are intertwined with health outcomes and thus may be considered as rele-
vant. Stakeholder groups have noted discomfort with using quality-adjusted 
life years (QALYs) because they do not capture all relevant factors and because 
of concerns about the methods used to obtain them (Roth et al. 2011). Further-
more, Greenberg and Neumann (2011) found that adjusting life years for quality 
of life does not substantively affect cost per life year ratios, at least for cancer-
related interventions.
These concerns illustrate the need for a broader conception of value and a 
range of metrics for its assessment. In lay terms, value is simply the importance 
of something. The economic concept of value further takes into account that 
value is relative – that it is based on a change in utility relative to a change in 
consumption – and that it involves tradeoffs with other goods or services. With 
this broader conception of value as a starting point, we can consider various 
approaches to measuring value, with the appropriate approach dependent on 
the question to be addressed and the relevant audience.
In addition to the various standard methods of valuation (cost-minimi-
zation analysis, cost-consequence analysis, CEA, and cost-benefit analysis), 
there are also various other approaches to measuring value that have emerged 
in recent years and that may be useful for evaluating PM. We discuss in this 
section several types that may prove relevant to economic evaluation of PM.
4.2  Resource Allocation Frameworks
Valuation methods such as CEA compare one intervention to another to examine 
incremental costs and effects, that is, they look at what is the “bang for the buck.” 
However, CEA does not address the broader questions of where PM could have the 
greatest impact (Phillips et al. 2005). A PM test could be relatively cost-effective 
but have little impact on population health or be unaffordable within a budget-
constrained environment.
Two resource allocation frameworks can be useful in evaluating these 
questions:
 – Burden of illness (also called cost of illness) studies examine the total costs 
incurred by society due to a specific disease.
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 – Budget impact studies (BIA) estimate the financial consequences of adop-
tion and diffusion of a new health care intervention within a specific health 
care setting or system given resource constraints. It has been recommended 
that a BIA accompany a CEA when payers are considering a new intervention 
since it is possible that a PM technology is efficient based on the CEA but not 
affordable based on the BIA due to the expected adoption and diffusion of 
the technology. (Mauskopf et al. 2007).
Budget impact and burden of illness studies shift the focus to the actual 
impact of interventions in the real world. Furthermore, their focus on afforda-
bi lity and population impact may be more politically palatable than a focus on 
cost-effectiveness.
To illustrate, we use the example of CYP2D6, which is one of the most studied 
drug-metabolizing enzymes that has been estimated to be responsible for meta-
bolizing 25% of drugs, including commonly-used ones such as anti-depressants, 
beta-blockers, and codeine (See http://youscript.com/healthcare-professionals/
what-is-youscript/pharmacogenetic-testing/cytochrome-p450-2d6-genotyping). 
Because CYP2D6 metabolizes an array of commonly used drugs, testing for 
CYP2D6 variants associated with slow or fast drug metabolism is likely to have 
implications not only for current drug utilization but also for future drug utili-
zation, because test results can be used over a lifetime. Testing will also have 
implications for total budgets because of the potential for widespread testing and 
follow-up.
Key questions in a resource allocation framework are: What are the sizes of 
the relevant populations? What are the costs associated with those populations? 
What is known about the association of genetic variation with drug metabolism, 
response and clinical outcomes? Table 1 illustrates measures for addressing these 
questions using the example of CYP2D6.
4.3  Value of Information Analysis
Value of information analysis (VOI) offers a formal approach to deciding when 
and what types of data to collect. Formal use of decision analysis and VOI  analysis 
can help determine whether an intervention should be adopted, whether addi-
tional evidence to further inform that decision is worth gathering, and what kind 
of information is of greatest value.
The use of VOI has recently been highlighted because of its emphasis in 
PCORI priorities. The Methodology Committee’s draft report notes that VOI is a 
valuable tool for determining PCORI’s funding priorities and they name it one 
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of the four key components to a framework for establishing research priorities 
(Myers et al. 2012). However, lack of familiarity has kept this method from being 
used as widely as it could be.
VOI also provides a useful framework for setting priorities for further research 
into CEA. An example of this approach applied to PM is a cost-utility study of gene 
Table 1 Summary of Measures in a Pharmacogenetics Resource-Allocation Framework.
Relevant measure Description CYP2D6 example
Relevant populations
 Mutation prevalence Measure of the size of the 
population in which testing 
could have an impact on 
outcomes
Prevalence of individuals 
with slow or rapid metabo-
lism due to CYP2D6 variant 
alleles
 Drug utilization Measure of the size of the 
population that could be 
tested
Utilization of drugs metabo-
lized by CYP2D6
  Prevalence of condition 
for which drug is used
Another measure of the size 
of the population that could 
be tested, but which includes 
individuals who are untreated 
or treated with another drug 
but for whom testing might be 
relevant
Prevalence for primary 
indications of drugs metabo-
lized by CYP2D6
Relevant costs
 Drug expenditures Measure of the potential 
outcomes of testing because 
testing could change the 
utilization of drugs
Expenditures on drugs 
metabolized by CYP2D6
 Condition expenditures Measure of the potential 
outcomes of testing because 
testing could change disease 
costs
Prevalence for primary 
indications of drugs metabo-
lized by CYP2D6
Association of genetic 
variation
  Mutation effect on drug 
outcomes
Measure of the potential 
impact of testing because 
mutations must be associ-
ated with drug metabolism, 
drug response and clinical 
outcomes in order for testing 
to have an impact
Relationship of CYP2D6 
variant alleles to variation in 
metabolism, drug response 
and clinical outcomes
Source: Phillips et al. (2005). Measuring the value of pharmacogenomics. Nat Rev Drug Discov 
4: 500–510.
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expression profiling for breast cancer (Hall et al. 2012). The VOI analysis was able 
to show that the most important recommendation for further cost-effectiveness 
research is for future researchers to collect additional retrospective or prospective 
information on recurrence rates.
4.4  Stated Choice Methods and Willingness-to-pay
Stated choice methods (often called conjoint analysis or discrete choice experi-
ments) measure preferences for constructed alternatives (Phillips et al. 2002). They 
are designed to provide information about individuals’ willingness to accept trade-
offs among features of multi-attribute products. The preferred alternative is chosen 
by respondents among alternative scenarios described by multiple factors. Based 
on the choices made by the respondent for a series of pairs of hypothetical alterna-
tives that systematically vary combinations of beneficial and harmful outcomes, we 
can estimate marginal rates of substitution (tradeoffs) among the factors. If cost is 
included as one of the attributes, willingness-to-pay can be estimated.
Willingness-to-pay could be a particularly important measure for evaluating 
PM because it may better reflect the value of information per se and the process 
of care, compared to other measures (Bridges et  al. 2011). Studies have shown 
that information may have value for individuals even if it is not actionable, such 
as information on Alzheimer’s risk (Neumann et al. 2012). However, there is wide 
debate over whether it is appropriate for payers to consider “intrinsic” value in 
coverage and reimbursement decisions because consumer demand for informa-
tion is much higher than our ability to pay for tests to obtain information that is not 
actionable. There are also concerns that willingness-to-pay studies may provide 
an inflated value because they do not adequately reflect budget  constraints – 
that even though survey respondents are told to consider the true cost to them 
(without insurance and relative to other goods and services) they are not able to 
do so given that most people have little sense of the true cost of health care they 
consume. There are also dilemmas about how to incorporate willingness-to-pay 
into value analyses. It can be used in cost-benefit analyses, but few of these are 
done. There have been attempts to better define how willingness-to-pay can be 
used in CEAs, but this remains a challenge (Polsky 2005).
4.5   Multi-Criteria Decision Analysis Including Risk-benefit 
Frameworks
There are a number of different systematic approaches for quantifying and com-
paring benefits and risks, often called “multi-criteria decision analysis” (Guo et al. 
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2010). The objective of these approaches is to promote evidence-based decision-
making by organizing and synthesizing information and incorporating stake-
holder perspectives. Such methods can help decision makers make more informed 
choices when faced with complex decisions involving several dimensions.
Two risk-benefit frameworks relevant to PM that might be considered as falling 
into this broad category are: (1) A risk-benefit framework for genetic testing that 
compares the certainty of evidence of value with the risk-benefit ratio – favor-
able, neutral, unfavorable (Veenstra et al. 2010), and (2) the Institute for Clinical 
and Economic Review (ICER) Integrated Evidence Rating™, which speaks both 
to comparative clinical effectiveness and comparative value and provides payers 
with a tangible tool uniquely designed to support value-based benefit designs, 
reimbursement strategies, and coverage policies.
4.6   Identify Key Factors in Determining the Value  
of Personalized Medicine
There are currently no consolidated databases of economic evaluations of PM and 
thus it is difficult to assess the value of PM and what factors determine its value. A 
consolidated database would enable comparisons across studies and interventions. 
Furthermore, if this database had information on the key factors that may impact 
value and adoption, it could provide greater understanding of how to maximize the 
value of PM. Although the Tufts Cost-Effectiveness Registry is a relevant database, 
it only includes a specific type of CEAs – cost-utility analyses – and it does not 
include the range of factors that could determine PM’s value and adoption.
Factors that could determine the value and adoption of PM include clinical 
and disease characteristics, test characteristics, and measures of ethical, legal, 
and social implications. For example:
 – Clinical characteristics of relevant disease
 – Health and economic burden of relevant disease
 – Analytical validity, clinical validity and clinical utility of test
 – Availability of testing
 – Regulatory status
 – Insurance coverage and reimbursement
 – Patient and provider preferences
 – Ethical concerns
 – Impact on family members
 – Stakeholder and advocacy support
 – Technology assessment and clinical guidelines
 – Impact on diverse populations
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Such a database could then be used to examine topics such as:
 – Assess the overall cost-effectiveness of PM technologies relative to other 
interventions.
 – Compare and contrast the cost-effectiveness of PM applications, including 
analyses stratified by the specific test or specific disease.
 – Identify factors that influence the cost-effectiveness of PM.
 – Identify opportunities to fill gaps and improve the quality of the PM evidence 
base.
 – Evaluate the policy implications of the findings, including which PM 
 technologies get adopted and used.
4.7  Use Real World Perspectives in Economic Analyses
The cost-effectiveness of a PM technology as actually implemented may vary 
from its cost-effectiveness under ideal circumstances – and both results can be 
important depending on the research question. There are several approaches 
to incorporating “real world” perspectives in economic analyses that could be 
more widely used. Although a major challenge has been the lack of real world 
data for inclusion in CEAs, with the advent of more patient centered outcomes 
research, it is likely that observational data will become more available and of 
higher quality.
One approach is to use data inputs derived from actual implementation in 
addition to or in lieu of data derived from controlled conditions. Guidelines rec-
ommend that CEAs use the “best” data available as inputs into CEA (Gold et al. 
1996). However, there has been limited discussion of whether the “best” data for 
PM analyses should be derived from controlled and standardized conditions – such 
as randomized clinical trials, high volume central labs, and academic medical 
centers – versus real world data – observational studies, low-volume community 
labs, and community practices – and the impact on the results. For example, as 
noted earlier, CEAs of HER2 testing have typically assumed that testing will be 
offered to the relevant population, that it will be accurate, and that treatment 
decisions will follow test results – all assumptions that have been questioned 
when examined using observational data from community settings.
Another approach is to include a base case scenario that reflects actual 
practice in addition to or in lieu of the “ideal” base case scenario. The choice of 
comparators in any CEA is a critical determinant of the CEA results. In the case 
of PM, it can make a large difference in the results if the new PM technology is 
compared to (1) practice as recommended by guidelines or (2) what patients and 
providers actually do. When there are discrepancies between the two, the choice 
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of comparator will have a large impact, e.g., a test to target statins where actual 
rates of taking statins as recommended is much lower than recommended by 
guidelines.
Lastly, analysts can use extensive sensitivity analyses to examine the impli-
cations of how a technology is being implemented or will be implemented. These 
analyses can examine both changing the structure of the model (e.g., compar-
ing the PM technology to both guidelines and to actual practice) and data inputs 
(e.g., assessing results using data inputs derived from ideal conditions and from 
actual practice).
4.8  Consider Patient Heterogeneity in Economic Analyses
Patient centered outcomes research (PCOR) and comparative effectiveness 
research (CER) have been criticized because they typically focus on characteri-
zing a therapy’s average net benefits (Garber and Tunis 2009; Philipson and 
Sun 2011). There is growing evidence that average net benefits may differ sub-
stantially from the net benefits obtained by individuals because of patient 
heterogeneity (variability). As a result, conventional PCOR/CER analysis may 
produce misleading results and faulty conclusions about a therapy’s value. 
CEA and other economic evaluations are not part of PCORI’s mandate, but the 
issues in assessing heterogeneity in CER/PCOR and CEA share some similar 
characteristics.
While there is a growing body of literature examining the impact of patient 
heterogeneity on treatment effects for CER/PCOR, there is less work on the impact 
of patient heterogeneity on economic evaluations. A conceptual framework 
developed by Sculpher demonstrates how calculation of average cost-effective-
ness can mask important variations among individual patients (Sculpher 2008). 
Case studies support this assertion. For example, preliminary findings looking 
at schizophrenia treatment found that the usual population subgroupings (e.g., 
age, gender, race) did not explain treatment effect variation and that coverage 
decisions based on average results are suboptimal (National Pharmaceutical 
Council 2011). Sculpher notes that the use of subgroup analysis in cost-effective-
ness analysis raises a number of methodological questions, including a need to 
define the possible sources of heterogeneity that exist, to assess how heteroge-
neity in model parameters should be estimated and how uncertainty should be 
appropriately quantified, and the appropriateness in terms of equity of using all 
or some of the subgroup analyses as a basis of decision making.
These issues are specifically relevant to PM because of its focus on indivi-
dual heterogeneity, particularly in terms of genetic characteristics. Thus methods 
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developed for analyzing PM can both benefit from and contribute to the devel-
opment of methods for appropriately assessing heterogeneity in CEA and CER/
PCOR. This is particularly true for a broad definition of PM that encompasses 
popu lations defined by various personal, clinical, and environmental character-
istics such as race, ethnicity, gender, and location.
PM further complicates CEA subgroup analysis because patient hetero-
geneity includes an array of sociodemographic characteristics and patient 
preferences, and their interaction with heterogeneity in tumor biology. Con-
sider the case of GEP for breast cancer. OncotypeDX™, the most commonly 
used GEP test in the USA, is currently indicated only for early-stage estrogen 
receptor-positive, lymph-node-negative breast cancers. Yet the aggressive form 
of breast cancer – triple negative breast tumors (estrogen receptor negative, 
progesterone-receptor negative, and HER2 negative) – are more common in 
young women in their 20s and 30s and black women. Thus, in conducting a 
CEA of GEP, generating subgroup data for black women, for example, may not 
be relevant for two reasons. First, fewer blacks than whites express estrogen 
receptor positive tumors, so a CEA focusing on blacks would most likely be 
inconclusive. Second, even among black women who are estrogen receptor 
positive, our review of the EGAPP Working Group report on GEP tests (Mar-
chionni et al. 2008) suggest that the clinical utility of GEP had not been vali-
dated across diverse populations (Odierna et al. 2011). Thus, for blacks, there is 
more uncertainty in the use of inputs used in evaluating the cost-effectiveness 
of OncotypeDX™.
Efforts to encompass a diverse population perspective in PM CEA could be 
improved in the following ways:
Increasing Representation: Diversity in PM studies includes both patient level 
diversity and tumor biology diversity. Recruiting diverse populations with differ-
ent biomarker expression in clinical trials would reduce the uncertainty of CEA 
subgroup estimates and make subgroup analysis more meaningful. As a first 
step, EGAPP could be more explicit in recommending that clinical trials of PM 
report race/ethnicity of its study participants, so that the assessment of effective-
ness across diverse populations is transparent.
Ensuring Collection: Utilization and outcome estimates for subgroups as 
inputs for PM CEA suffer the same limitations as most other CEAs – self-reported 
race/ethnicity and self-reported income have a high percentage of missing values 
in these datasets. An Institute of Medicine (IOM) report (2009) estimates that up 
to 70% of race/ethnicity are missing in claims data. Imputed data on race/ethni-
city offer a proxy measure for analysis, but encouraging health plans to collect 
self-reported data would facilitate accuracy of inferences from subgroup analysis 
for PM CEA and CEA in general.
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4.9   Prepare for Upcoming Challenges of Assessing  
Value of Emerging Technologies
The rapid technological advances in PM threaten to outpace our ability to use 
these interventions effectively in clinical practice and to address the associated 
health policy issues. This is particularly true for the much awaited “affordable 
genome” – the ability to sequence an individual’s or a tumor’s entire genome 
quickly and inexpensively. Whole genome sequencing is now being offered in 
clinical care and is expected to become more widely used in the near future, par-
ticularly in cancer. Whether whole genome sequencing can achieve its potential 
to improve patient outcomes will depend on how patients and providers value 
the information provided, whether whole genome sequencing will be covered by 
payers and recommended in guidelines, and whether the economic value to the 
health care delivery system outweighs the costs. Yet, assessing the value of whole 
genome sequencing is complex because it provides not just one test result but a 
multitude of results that range from clinically actionable findings (treatable or 
preventable), to not directly actionable findings (with unclear treatment implica-
tions), to findings of unknown significance (Figure 5). There are also concerns 
that some information could be harmful if there are no available or acceptable 
treatments or if the information leads to confusion or unwarranted health care.
Thus, an important research need is to develop a framework to conceptualize, 
identify, and define needed data to assess the value of whole genome sequencing. 
It would be infeasible and unhelpful to simply propose a CEA of whole genome 
sequencing versus no whole genome sequencing in its entirety. Such an analysis 
would be overwhelming in its complexity: there are too many possible research 
questions, pathways, and outcomes because a whole genome sequencing report 
Types of information
Clinically actionable
Not directly clinically
actionable
Unknown or no clinical
significance
No additional information
WGS
WGS
WGS
testing
decision
No
Test
Test
Treat
Do not treat
Treatment
decisions Outcomes
Health
benefits
Costs
Tests
Anxiety
Regret
Side
effects
Figure 5 WGS Testing Process and Outcomes.
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provides information about multiple variants, each of which has its own pro b-
abilities, resulting treatment choices, and downstream consequences to consider, 
many of which have not yet been defined. Furthermore, a comprehensive analysis 
of whole genome sequencing needs to consider non-monetary risks and benefits 
that may not be adequately captured by standard CEA methods.
4.10   Incorporate Behavioral Economics into  
Value Assessments
Behavioral economics is the combined discipline of psychology and economics 
that investigates what happens in markets in which agents display human limita-
tions and complications. Seminal work was conducted by Tversky and Kahne-
man in the 1970s, and Kahneman received the Nobel Prize in Economics for his 
work in 2002 – the first psychologist to do so. (Tversky and Kahneman 1974; Kah-
neman and Tversky 1979).
Only recently has behavioral economics been applied to health care (Rice 
2013). PubMed did not have a MeSH term for behavioral economics until 2012. 
There are many examples of where individuals make health decisions that are 
contrary to rational economic theory, such as failing to enroll in health insurance 
to which they are entitled or engaging in harmful health behaviors. Behavioral 
economics offers a means by which to explain and influence such behaviors. 
One well-known example is the framing effect, an example of cognitive bias, in 
which people react differently to a particular choice depending on whether it is 
presented as a loss or as a gain, e.g., individuals perceive “this operation has an 
80% survival rate” differently than “you have a 20% chance of dying.” Studies 
applying behavioral economics have looked at issues such as how to incentivize 
healthier choices and using default choices and “nudges” to improve decision-
making (e.g., Halpern et al. 2007; Volpp et al. 2011).
To our knowledge, behavioral economics has not been directly applied to the 
analysis of decision-making and value for PM. There have been studies of the 
behavioral impact of genetic testing, such as the Scripps Health study on direct 
to consumer genetic testing that found that participants who received test results 
did not suffer test-related distress, but that testing also had little impact on posi-
tive behavior changes (Bloss et al. 2011). However, such studies do not appear to 
have directly used behavioral economic theories.
Behavioral economics could offer rich possibilities for better understanding 
of the implications of PM and how to most appropriately frame related decision-
making at both the individual and collective levels. For example, there are many 
unanswered questions about how individuals perceive genetic test information 
S48      Kathryn A. Phillips et al.
and whether cognitive biases are the same in this type of decision-making as 
with other decisions or whether “genetic exceptionalism” applies. Studies of 
PM could also benefit from drawing on the rich literature on cognitive biases 
in diagnoses, given that most PM involves diagnostic testing. For example, it is 
well-established that patients and physicians overweight small probabilities and 
underweight large probabilities, in accordance with prospect theory as developed 
by Kahneman and Tversky (Elstein and Schwarz 2002). This “compression” of the 
pro bability scale explains why the difference between 99 and 100% is psychologi-
cally much greater than the difference between, say, 60 and 61%. These issues 
are particularly important as we consider the implications of whole genome 
sequencing, because one of the key unanswered questions is how to deal with the 
dilemma that arises when patients say that they want to know all of the informa-
tion from sequencing – even if it is useless and may be harmful – given that most 
patients do not understand the probabilities and tradeoffs involved.
Our work with Reed Johnson at RTI International illustrates how economic 
analyses could benefit from the application of behavioral analyses (Johnson 
et al. 2011). This study assessed the consequences of estimating willingness-to-
pay assuming a linear opportunity–cost specification when actual preferences 
may be inconsistent with that specification. Willingness-to-pay estimates derived 
from stated choice studies generally assume that the marginal utility of income 
is constant. We analyzed the results of five studies that allow direct tests of this 
assumption. Tests indicated that marginal utility often violates theoretical expec-
tations. We suggested that this result is an artifact of a cognitive heuristic that 
recodes cost levels from a numerical scale to qualitative categories. Instead of 
evaluating nominal costs in the context of a budget constraint, subjects may 
recode costs into categories such as “low,” “medium,” and “high,” and choose as 
if the differences between categories were equal. This simplifies the choice task 
but undermines the validity of willingness-to-pay estimates as welfare measures. 
Recoding may be a common heuristic in healthcare applications when insurance 
coverage distorts subjects’ perception of the nominal costs presented. Recoding 
may also distort estimates of marginal rates of substitution for other attributes 
with numeric levels. Thus, there is an important role in using behavioral eco-
nomics to better understand how cost is perceived.
In conclusion, PM offers many opportunities as well as challenges. A particu-
larly important challenge is defining and measuring its value. We have outlined 
six areas for future research, ranging from applying existing methods to PM to 
breaking new ground through development of new conceptual frameworks and 
methods. By moving ahead on this research agenda, economists can help ensure 
that these new technologies have a favorable impact on clinical care and health 
policy.
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